Health
Trump’s Tariff Threat Sparks Race to Find US Drug Manufacturers
Even before Trump took office, drugmakers were moving more manufacturing to the US because of the rising threat of natural disasters, outbreaks like Covid and pending legislation that underscored the risks of far-flung supply chains.
Photographer: Paul Yeung/BloombergThis article is for subscribers only.
Supply Lines is a daily newsletter that tracks global trade. Sign up here.
Drug manufacturers are rushing to reshape their supply chains amid President Donald Trump’s escalating tariff threats, leading to a potential windfall for contractors that make medications in the US.